Received Mar 24, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | 3 | CT3Z7 | — |
Maladministration of Adult Dose on an Pediatric Patient; Overdose; This non-serious case was reported by a other health professional via call center representative and described the occurrence of adult product administered to child in a 15-year-old male patient who received HBV (Engerix B adult) (batch number CT3Z7, expiry date 13-FEB-2027) for prophylaxis. On 12-MAR-2025, the patient received the 3rd dose of Engerix B adult. On 12-MAR-2025, an unknown time after receiving Engerix B adult, the patient experienced adult product administered to child (Verbatim: Maladministration of Adult Dose on an Pediatric Patient) and overdose (Verbatim: Overdose). The outcome of the adult product administered to child and overdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 14-MAR-2025 The patient came and was due to the Engerix-B third dose, and adult dose was given to the pediatric patient, which led adult product administered to child and overdose. The reporter consented to follow up.